Fresenius Medical Care AG (FMCQF)
| Market Cap | 14.62B |
| Revenue (ttm) | 22.92B |
| Net Income (ttm) | 770.90M |
| Shares Out | n/a |
| EPS (ttm) | 2.62 |
| PE Ratio | 18.97 |
| Forward PE | 10.74 |
| Dividend | 1.62 (3.18%) |
| Ex-Dividend Date | May 23, 2025 |
| Volume | 475 |
| Average Volume | 2,396 |
| Open | 51.06 |
| Previous Close | 52.15 |
| Day's Range | 51.06 - 51.06 |
| 52-Week Range | 35.45 - 61.84 |
| Beta | 0.86 |
| RSI | 50.01 |
| Earnings Date | Aug 5, 2025 |
About Fresenius Medical Care AG
Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, the United States, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient’s residence; and dialysis services under contract to hospitals in the United States for the hospital... [Read more]
Financial Performance
In 2024, Fresenius Medical Care AG's revenue was 19.34 billion, a decrease of -0.61% compared to the previous year's 19.45 billion. Earnings were 537.91 million, an increase of 7.80%.
Financial numbers in EUR Financial StatementsNews
Fresenius Medical Care announces first tranche of its share buyback program of up to EUR 600 million as part of its new capital allocation framework
Total volume of the initial share buyback is up to EUR 1 billion over two years Share buyback to take place until August 10, 2027 BAD HOMBURG, Germany , Aug. 11, 2025 /PRNewswire/ -- Fresenius Medical...
Fresenius Medical Care AG (FMS) Q2 2025 Earnings Call Transcript
Fresenius Medical Care sees limited impact from tariffs, says CEO
Helen Giza, Fresenius Medical CEO discusses the impact of tariffs on the business
Fresenius Medical Care reports Q2 results
Fresenius Medical Care delivers strong organic revenue growth and double-digit operating income growth in the second quarter of 2025
Strong organic revenue growth1 of 7% driven by all operating segments Stable U.S. same market treatment development driven by accelerating patient inflow FME25+ savings of EUR 58 million contributed t...
Fresenius Medical Care: Is Trading Below Its Intrinsic Value (Buy)
Fresenius Medical Care (FMS) shows strong growth, with shares up 32.95% YoY and net income up 60%.
$6.3 Trillion Outpatient Clinics Markets, 2021-2024 & 2025-2029 | Profiles of Leading Players - Johns Hopkins Medicine, Mayo Clinic, MD Anderson Cancer Center, Apollo Hospital, and Fresenius Medical
Explore the latest report on the global outpatient clinics market, analyzing trends, revenue, and forecasts from 2023 to 2029. This comprehensive study covers services, specialty, regional insights, a...
Fresenius Medical in-pact with Coordination of National Institutes in Mexico
Fresenius Medical Care Collaborates with Coordination of National Institutes of Health and Specialty Hospital to Extend Access to Innovative Dialysis Therapy in Mexico
High-Volume Hemodiafiltration is used for the first time in seven out of 10 CCINSHAE centers in Mexico In Mexico, 240 CCINSHAE patients are now being treated; more than 410 regular patients also treat...
Fresenius Medical Care initiates €1B share buyback
Fresenius Medical Care Launches Value-Based Care Segment, Eyes Growth Through Innovation, Efficiency
Fresenius Medical Care AG (NYSE: FMS) on Tuesday introduced a strategic roadmap — FME Reignite — aimed at revitalizing its core business, driving innovation and reshaping its organizational culture. ...
Fresenius Medical Care Launches Value-Based Care Segment, Eyes Growth Through Innovation, Efficiency
Fresenius Medical Care AG FMS on Tuesday introduced a strategic roadmap — FME Reignite — aimed at revitalizing its core business, driving innovation and reshaping its organizational culture.
Fresenius Medical Care CEO Says Company Could Benefit From Obesity Drugs
EXCLUSIVE: The dialysis company believes the impact of the treatments on its own performance will be ‘neutral to positive' rather than negative.
Fresenius Medical Care Launches its Strategy FME Reignite with increased Profitability Aspirations, and a New Capital Allocation Framework to further enhance Value Creation
FME Reignite sets the ambition to lead kidney care through exceptional patient care and innovation The Company will set the new standard of care in the U.S. with the introduction of the 5008X dialysis...
Fresenius Medical Care announces 1 bln euros share buyback programme
The world's largest dialysis specialist Fresenius Medical Care said, ahead of its capital markets day on Tuesday, that it plans to embark on a 1 billion euros ($1.16 billion) share buyback programme.
5 Stocks To Ride The German Market Rally
Stocks in the United States have struggled to regain their February all-time highs amid the tariff uncertainty. In fact, the S&P 500 remains one of the worst-performing major stock indices in the deve...
Fresenius Medical Care Begins Broader U.S. Commercialization of 5008X™ CAREsystem, Achieves Key Milestones in Efforts to Introduce High-Volume Hemodiafiltration Dialysis Therapy to Individuals with Kidney Disease in the U.S.
Updated 5008X CAREsystem with Additional Features Receives FDA 510(k) Clearance Company announces first wave of Fresenius Kidney Care clinics in the U.S. to begin offering high-volume hemodiafiltrati...
Fresenius Medical Care presents its new research and innovation for kidney care at European Renal Association Congress 2025
Key abstract presentations showcase significant advancements in clinical care, artificial intelligence, and fluid management, demonstrating Fresenius Medical Care's commitment to improving patient out...
Fresenius Medical Care Annual General Meeting: Strong Performance Against Its Strategic Plan Results in Highest Dividend per Share in Its History
Shareholders approved the proposed dividend of 1.44 Euro per share, representing a 21 percent increase year-over-year and marking the highest dividend in the company's history Excellent progress in th...
Fresenius Medical Care AG 2025 Q1 - Results - Earnings Call Presentation
Fresenius Medical Care AG (FMS) Q1 2025 Earnings Conference Call Transcript
Fresenius Medical Care Non-GAAP EPS of €0.84, revenue of €4.88B; reaffirms FY25 outlook
Fresenius Medical Care starts 2025 with strong organic revenue and income growth
Strong organic revenue growth1 of 5% driven by Care Enablement and Care Delivery Stable U.S. same market treatment development despite impact from a severe flu season FME25 savings of EUR 68 million c...
Fresenius Medical Care tops market expectations in 1st quarter
World's largest dialysis specialist Fresenius Medical Care reported first-quarter results above analysts' expectations on Tuesday, as revenue grew organically in all its segments, it said.